


SUSTAIN trials

ESTIMATED CHANGE IN HbA_{1c}




*p<0.0001 vs comparator.

Exenatide OW, exenatide once weekly; IGLar, insulin glargine.

1. Sorli et al. *Lancet Diabetes Endocrinol* 2017;5:251–260; 2. Ahrén et al. *Lancet Diabetes Endocrinol* 2017;5:341–354; 3. Ahmann et al. *Diabetes Care* 2018;41:258–266; 4. Aroda et al. *Lancet Diabetes Endocrinol* 2017;5:355–366; 5. Rodbard et al. *The Journal of Clinical Endocrinology and Metabolism* 2018, 103(6):2291–2301; 6. Pratley et al. *Lancet Diabetes Endocrinol* 2018; 6(4):275–286

SUSTAIN trials

ESTIMATED MEAN CHANGE IN BODY WEIGHT



*p<0.0001 vs comparator.

Exenatide OW, exenatide once weekly; IGLar, insulin glargine.

1. Sorli et al. *Lancet Diabetes Endocrinol* 2017;5:251–260; 2. Ahrén et al. *Lancet Diabetes Endocrinol* 2017;5:341–354; 3. Ahmann et al. *Diabetes Care* 2018;41:258–266; 4. Aroda et al. *Lancet Diabetes Endocrinol* 2017;5:355–366; 5. Rodbard et al. *The Journal of Clinical Endocrinology and Metabolism* 2018, 103(6):2291–2301; 6. Pratley et al. *Lancet Diabetes Endocrinol* 2018; 6(4):275–286